| Ident. | Authors (with country if any) | Title |
|---|
| 000190 (2020) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Response to: 'Some concerns from Turkey' by Bilgin et al. |
| 000905 (2019) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonori Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Response to: 'Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment' by Lee. |
| 000C71 (2019) |
Yuya Fujita [Japon] ; Masao Nawata [Japon] ; Atsushi Nagayasu [Japon] ; Kazuki Someya [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] | Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report |
| 001129 (2018) |
Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Kei Ikeda [Japon] ; Tomonoti Ishii [Japon] ; Kosaku Murakami [Japon] ; Hyota Takamatsu [Japon] ; Yoshiya Tanaka [Japon] ; Takayuki Abe [Japon] ; Tsutomu Takeuchi [Japon] | Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. |
| 001141 (2018) |
Yuko Kaneko [Japon] ; Masaru Kato [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekara Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon] | Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study). |
| 001396 (2018) |
Yoshikazu Nakaoka [Japon] ; Mitsuaki Isobe [Japon] ; Syuji Takei [Japon] ; Yoshiya Tanaka [Japon] ; Tomonori Ishii [Japon] ; Shumpei Yokota [Japon] ; Akira Nomura [Japon] ; Seitaro Yoshida [Japon] ; Norihiro Nishimoto [Japon] | Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). |
| 001423 (2018) |
Shingo Nakayamada [Japon] ; Satoshi Kubo [Japon] ; Maiko Yoshikawa [Japon] ; Yusuke Miyazaki [Japon] ; Naoki Yunoue [Japon] ; Shigeru Iwata [Japon] ; Ippei Miyagawa [Japon] ; Shintaro Hirata [Japon] ; Kazuhisa Nakano [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] | Differential effects of biological DMARDs on peripheral immune cell phenotypes in patients with rheumatoid arthritis. |
| 001C22 (2016) |
Satoshi Kubo [Japon] ; Shingo Nakayamada [Japon] ; Kazuhisa Nakano [Japon] ; Shintaro Hirata [Japon] ; Shunsuke Fukuyo [Japon] ; Ippei Miyagawa [Japon] ; Kentaro Hanami [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] | Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. |
| 001C25 (2016) |
Yuko Kaneko [Japon] ; Tatsuya Atsumi [Japon] ; Yoshiya Tanaka [Japon] ; Masayuki Inoo [Japon] ; Hitomi Kobayashi-Haraoka [Japon] ; Koichi Amano [Japon] ; Masayuki Miyata [Japon] ; Yohko Murakawa [Japon] ; Hidekata Yasuoka [Japon] ; Shintaro Hirata [Japon] ; Hayato Nagasawa [Japon] ; Eiichi Tanaka [Japon] ; Nobuyuki Miyasaka [Japon] ; Hisashi Yamanaka [Japon] ; Kazuhiko Yamamoto [Japon] ; Tsutomu Takeuchi [Japon] | Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). |
| 002637 (2014) |
Takao Koike [Japon] ; Masayoshi Harigai [Japon] ; Shigeko Inokuma [Japon] ; Naoki Ishiguro [Japon] ; Junnosuke Ryu [Japon] ; Tsutomu Takeuchi [Japon] ; Syuji Takei [Japon] ; Yoshiya Tanaka [Japon] ; Yoko Sano [Japon] ; Hitomi Yaguramaki [Japon] ; Hisashi Yamanaka [Japon] | Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan |
| 002858 (2013) |
John J. O'Shea [États-Unis] ; Apostolos Kontzias [États-Unis] ; Kunihiro Yamaoka [Japon] ; Yoshiya Tanaka [Japon] ; Arian Laurence [États-Unis] | Janus kinase inhibitors in autoimmune diseases |
| 002874 (2013) |
Josef S. Smolen [Autriche] ; Monika M. Schoels [Autriche] ; Norihiro Nishimoto [Japon] ; Ferdinand C. Breedveld [Pays-Bas] ; Gerd R. Burmester [Allemagne] ; Maxime Dougados [France] ; Paul Emery [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Cem Gabay [Suisse] ; Allan Gibofsky [États-Unis] ; Juan Jesus Gomez-Reino [Espagne] ; Graeme Jones [Australie] ; Tore K. Kvien [Norvège] ; Miho Murakami [Japon] ; Neil Betteridge [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Vivian Bykerk [Suisse] ; Ernest H. Choy [Royaume-Uni] ; Bernard Combe [France] ; Maurizio Cutolo [Italie] ; Winfried Graninger [Autriche] ; Angel Lanas [Espagne] ; Emilio Martin-Mola [Espagne] ; Carlomaurizio Montecucco [Italie] ; Mikkel Ostergaard [Danemark] ; Karel Pavelka [République tchèque] ; Andrea Rubbert-Roth [Allemagne] ; Naveed Sattar [Royaume-Uni] ; Marieke Scholte-Voshaar [Suisse] ; Yoshiya Tanaka [Japon] ; Michael Trauner [Autriche] ; Gabriele Valentini [Italie] ; Kevin L. Winthrop [États-Unis] ; Maarten De Wit [Pays-Bas] ; Désirée Van Der Heijde [Pays-Bas] | Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions |
| 002C13 (2013) |
S. Hirata [Japon] ; W. Li [États-Unis] ; N. A. Defranoux [États-Unis] ; R. Bolce [États-Unis] ; D. J. Haney [États-Unis] ; E. H. Sasso [États-Unis] ; S. Kubo [Japon] ; S. Fukuyo [Japon] ; Y. Mizuno [Japon] ; K. Yamaoka [Japon] ; K. Saito [Japon] ; Y. Tanaka [Japon] | SAT0012 A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score is Associated with Radiographic Outcomes in RA Patients Treated with TNF Inhibitors |
| 002D99 (2013) |
K. Saito [Japon] ; K. Hanami [Japon] ; S. Hirata [Japon] ; S. Kubo [Japon] ; M. Nawata [Japon] ; K. Yamaoka [Japon] ; S. Nakayamada [Japon] ; K. Nakano [Japon] ; Y. Tanaka [Japon] | FRI0251 Comparison of lipid profile including high molecular weight adiponectin (HMW-AN) after treatment with three different biologics in the patients with bio-naïve rheumatoid arthritis (RA) |
| 002E53 (2013) |
K. Hanami [Japon] ; K. Saito [Japon] ; H. Tasaka [Japon] ; Y. Tanaka [Japon] | FRI0190 CDAI is a predictor of physical function and bone destruction at week 52 in RA patients |
| 002F13 (2013) |
K. Hanami [Japon] ; S. Hirata [Japon] ; H. Tasaka [Japon] ; W. Li [États-Unis] ; R. Bolce [États-Unis] ; E. H. Sasso [États-Unis] ; N. A. Defranoux [États-Unis] ; K. Yamaoka [Japon] ; K. Saito [Japon] ; Y. Tanaka [Japon] | FRI0066 Behavior of the multi-biomarker disease activity (vectra da algorithm) score and components in patients with rheumatoid arthritis treated with tocilizumab |
| 003564 (2012) |
Y. Tanaka [Japon] ; Y. Maeshima [Japon] ; K. Yamaoka [Japon] | In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis |
| 003572 (2012) |
Ryoko Sakai [Japon] ; Michi Tanaka [Japon] ; Toshihiro Nanki [Japon] ; Kaori Watanabe [Japon] ; Hayato Yamazaki [Japon] ; Ryuji Koike [Japon] ; Hayato Nagasawa [Japon] ; Koichi Amano [Japon] ; Kazuyoshi Saito [Japon] ; Yoshiya Tanaka [Japon] ; Satoshi Ito [Japon] ; Takayuki Sumida [Japon] ; Atsushi Ihata [Japon] ; Yoshiaki Ishigatsubo [Japon] ; Tatsuya Atsumi [Japon] ; Takao Koike [Japon] ; Atsuo Nakajima [Japon] ; Naoto Tamura [Japon] ; Takao Fujii [Japon] ; Hiroaki Dobashi [Japon] ; Shigeto Tohma [Japon] ; Takahiko Sugihara [Japon] ; Yukitaka Ueki [Japon] ; Akira Hashiramoto [Japon] ; Atsushi Kawakami [Japon] ; Noboru Hagino [Japon] ; Nobuyuki Miyasaka [Japon] ; Masayoshi Harigai [Japon] | Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules |
| 003631 (2012) |
P. P. Tak [Pays-Bas] ; P. J. Mease [États-Unis] ; M. C. Genovese [États-Unis] ; J. Kremer [États-Unis] ; B. Haraoui [Canada] ; Y. Tanaka [Japon] ; C. O. Bingham Iii [États-Unis] ; A. Ashrafzadeh [États-Unis] ; H. Travers [Royaume-Uni] ; S. Safa-Leathers [Royaume-Uni] ; S. Kumar [Royaume-Uni] ; W. Dummer [États-Unis] | Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty‐eight–week randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial |
| 003697 (2012) |
Tomoyuki Imagawa [Japon] ; Syuji Takei [Japon] ; Hiroaki Umebayashi [Japon] ; Kenichi Yamaguchi [Japon] ; Yasuhiko Itoh [Japon] ; Toshinao Kawai [Japon] ; Naomi Iwata [Japon] ; Takuji Murata [Japon] ; Ikuo Okafuji [Japon] ; Mari Miyoshi [Japon] ; Yasuhiro Onoe [Japon] ; Yoshifumi Kawano [Japon] ; Noriko Kinjo [Japon] ; Masaaki Mori [Japon] ; Neelufar Mozaffarian [États-Unis] ; Hartmut Kupper [Allemagne] ; Sourav Santra [Inde] ; Gina Patel [États-Unis] ; Shinichi Kawai [Japon] ; Shumpei Yokota [Japon] | Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan |
| 003995 (2011) |
Takao Koike [Japon] ; Masayoshi Harigai [Japon] ; Shigeko Inokuma [Japon] ; Naoki Ishiguro [Japon] ; Junnosuke Ryu [Japon] ; Tsutomu Takeuchi [Japon] ; Syuji Takei [Japon] ; Yoshiya Tanaka [Japon] ; Kyoko Ito [Japon] ; Hisashi Yamanaka [Japon] | Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients |
